'As of yet, none of the improved IL-2-based compounds gained regulatory approval for the treatment of cancer or autoimmune diseases. Three compounds treating cancer have entered phase 3 trials with two studies still ongoing. NKTR-214 is the only compound that has completed phase 3 studies.'

#Immunology #Immunotherapy #IL2 #Preprint

https://www.medrxiv.org/content/10.1101/2022.12.02.22283042v1